EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice ofEndocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advancedor Metastatic Breast Cancer Previously Treated with Endocrine Therapy

Contact:

NCT Number:

Protocol:

AAAT8041

Study Status:

Active/Enrolling

Population:

Adult

Phase:

III

This study is being done to see how safe an investigational drug, LY3484356 is and how well it will work to help people with estrogen receptor positive (ER+), HER2 negative (HER2-) locally advanced or metastatic breast cancer previously treated with endocrine therapy. The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research question: How LY3484356 compares to investigator’s choice of either fulvestrant or exemestane for the treatment of ER+, HER2- breast cancer.

Are you Eligible? (Inclusion Criteria)

  • Must be able to swallow capsules/tablets
  • Must not have a serious heart condition
  • Must not have a history of any other cancer

Specialty Area(s)

Breast Cancer, Immunotherapy

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032